Earlier in March, Mitologics participated in the RespiriTB consortium 2025 annual Meeting in Vienna. A heartfelt thank you to our hosts, the Medical University of Vienna (MUW). It was a pleasure seeing many of you in person.
This significant milestone was the occasion to learn more about the ongoing phase 1 clinical assay. It also saw many final reports from our colleagues on their contributions since 2019. Consequently, Mitologics reported on its input within the “CMC development and Toxicology up to NME declaration” work package, which involved mitochondrial toxicity tests on several molecules, from Hit-to-Lead phase to NME declaration, and allowed their selection and classification. Last, we agreed that some of the drug discovery projects will continue.
Mitologics remains very proud of being part of the RespiriTB consortium which tackled tuberculosis, which, according to the last WHO position, dating from March 2025, “has probably returned to being the world’s leading cause of death from a single infectious agent, following three years in which it was replaced by coronavirus disease (COVID-19).” Unfortunately, in 2023 alone, a total of 1.25 million people died from this disease. That’s why ending the TB epidemic by 2030 remains among the health targets of the United Nations Sustainable Development Goals (SDGs).
Mitologics would like to thank the Innovative Health Initiative (IHI). This world’s biggest public-private partnership in the life sciences facilitates collaboration between the European Commission and industry partners.
Learn more https://respiritbntm.eu/News.html
